Kaye Randall 4
4 · Longboard Pharmaceuticals, Inc. · Filed Oct 16, 2024
Insider Transaction Report
Form 4
Kaye Randall
CMO
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-10-15−16,667→ 96,300 totalExercise: $4.35Exp: 2033-02-08→ Common Stock (16,667 underlying) - Exercise/Conversion
Common Stock
2024-10-15$4.35/sh+16,667$72,501→ 34,587 total - Sale
Common Stock
2024-10-15$59.03/sh−16,667$983,936→ 17,920 total
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- [F2]The amount reported includes the 17,920 restricted stock units (RSUs) that were granted on February 8, 2024, and reported in a Form 4 filed on February 9, 2024. The RSUs will vest in four equal annual installments commencing on February 8, 2025, and the shares underlying the RSUs will be issued upon vesting and release of the RSUs.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.88 to $59.10, inclusive. The reporting person undertakes to provide Longboard Pharmaceuticals, Inc., any security holder of Longboard Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
- [F4]The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023.